Shots:
- Daiichi Sankyo has dosed the first patient with Enhertu in combination with Keytruda in the P-III (DESTINYLung06) trial as a 1L treatment for unresectable, LA/M HER2 overexpressing & PD-L1 (TPS<50%) non-squamous NSCLC
- Trial will assess Enhertu (5.4mg/kg) + Keytruda vs Keytruda + Pt-based CT + pemetrexed as the 1L treatment in the mentioned pts (n=~686), evaluating PFS per BICR as the 1EP & OS as the key 2EP, while other 2EPs incl. investigator-assessed PFS, ORR, DoR per BICR & investigator, plus safety
- Daiichi Sankyo discovered Enhertu, which is being jointly developed & commercialized by Daiichi Sankyo & AstraZeneca; based on various studies, Enhertu is approved in 85+ countries
Ref: Daiichi Sankyo | Image: Daiichi Sankyo| Press Release
Related News:- Daiichi Sankyo Reports the Health Canada’s Approval of Enhertu for HER2 Low/Ultralow Metastatic Breast Cancer (MBC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
